基于结构的新型共价可逆双TLR2/TLR9小分子抗剂的设计,合成和鉴定
Srinivasa Reddy Natala1, Agata Habas2, Emily M Stocking2
1ChemDiv, Inc., 12730 High Bluff Dr. #100, San Diego, CA 92130, USA.
Bioorganic & medicinal chemistry letters
|April 28, 2025
概括
新型双Toll-like受体2/9 (TLR2/9) 抗剂被开发用于针对神经退行性疾病和癌症中的炎症. 这些化合物在治疗由TLR2/9介导的炎症驱动的疾病方面表现有前途.
科学领域:
- 免疫学 免疫学 免疫学
- 神经科学是一个神经科学.
- 在瘤学瘤学.
背景情况:
- 炎症是神经退行性疾病 (例如帕金森病,ALS) 和癌症 (例如胰腺癌,质母细胞瘤) 的关键因素.
- 收费类受体 (TLRs),特别是TLR2和TLR9,是中枢神经系统 (CNS) 和外围系统中炎症反应的关键调解者.
- 激活TLR2和TLR9有助于疾病的发病,而它们的非激活在临床前模型中显示出治疗效益.
研究的目的:
- 确定和开发针对TLR2和TLR9的新型治疗剂,用于治疗炎症性中枢神经系统疾病和恶性瘤.
- 设计和合成一种新的双TLR2/9对抗剂类别,基于TLR2/9TIR域中的关键结合位点.
主要方法:
- 利用TLR2/9 TIR域中的一个关键结合位置来指导可逆共价药物 (RCD) 的设计.
- 合成了一系列新的双TLR2/9对抗剂.
- 评估了使用特定激动剂抑制TLR2和TLR9信号传递的对抗剂的效力和特异性.
- 在实验室中评估了ADME (吸收,分布,新陈代谢和分泌) 和对抗剂类型的安全性概况.
主要成果:
- 在TLR2/9 TIR域中确定了一个关键的结合位点,使得双抗体的设计成为可能.
- 开发了一系列新型的双重TLR2/9抗剂,其微小分子度抑制TLR2和TLR9信号传导.
- 证明抗体可以选择性地抑制TLR2和TLR9,而不会激活其他TLR.
- 观察到有利的体内ADME和开发的对抗剂类型的安全概况.
结论:
- 双TLR2/9对抗是一种潜在的可行的治疗策略,用于由炎症驱动的疾病.
- 这里描述的双重TLR2/9对抗剂的新型系列显示出治疗神经退行性疾病和癌症具有炎症成分的前景.
- 这些抗体的进一步开发可能会导致一系列衰弱性疾病的有效治疗方法.
相关概念视频
01:28Structure-Activity Relationships and Drug Design
469
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
469
01:25Drug-Receptor Bonds
2.6K
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
In...
2.6K
01:29The Two-State Receptor Model
1.8K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
1.8K
02:40Ligand Binding Sites
12.6K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
12.6K